Results 201 to 210 of about 47,932 (337)

Placebo Effect Sizes in Clinical Trials of Knee Osteoarthritis Using Intra‐Articular Injections of Biologic Agents

Arthritis Care &Research, EarlyView.
Objective Patients with knee osteoarthritis rely on symptomatic treatments, in which up to 75% of the pain reduction can be attributed to the placebo effect. This effect may vary based on treatment type (eg, biologics vs nonbiologic injection) and route of administration (eg, intra‐articular vs topical vs oral).
Johanna M. Borst, Severin Ruoss, Ian Palmer, Trevor Smith, Kenneth Kalunian, Samuel R. Ward   +5 more
wiley   +1 more source

Ontologies and Data Management: A Brief Survey. [PDF]

Kunstliche Intell (Oldenbourg), 2020
Schneider T, Šimkus M.
europepmc   +1 more source

The complexity of verifying population protocols. [PDF]

Distrib Comput, 2021
Esparza J, Jaax S, Raskin M, Weil-Kennedy C.   +3 more
europepmc   +1 more source

Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to examine patient‐reported treatment goals among individuals with psoriatic arthritis. Methods Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient‐reported outcome (PROs) instruments, between 2017 and 2020.
Astia Allenzara, Kathleen Bush, M. Elaine Husni, Soumya M. Reddy, Jose U. Scher, Ethan Craig, Joelle Koplin, Jessica A. Walsh, Alexis Ogdie   +8 more
wiley   +1 more source

Analysis of the Longitudinal Behavior of Serum Levels of Soluble Flt1 and Placental Growth Factor in Pregnant Patients With Systemic Lupus Erythematosus

Arthritis Care &Research, EarlyView.
Objective This study analyzed longitudinal trajectories of soluble Flt1 (sFlt1) levels, placenta growth factor (PlGF) levels, and sFlt1:PlGF ratios in a cohort of pregnant patients with systemic lupus erythematosus (SLE). Methods Blood samples were collected (14–18, 24–26, 30–32, 34–36, and 38–40 weeks), stored at −80°C, and evaluated for serum levels ...
Nilson R. de Jesús, Guilherme R. de Jesús, Marcela I. Lacerda, Flávia C. dos Santos, Jeane de S Nogueira, Luiz Cristóvão Porto, Evandro S. F. Coutinho, Evandro M. Klumb   +7 more
wiley   +1 more source

Documentary analysis of national and international guidance for community clinicians referring patients with suspected chronic limb-threatening ischaemia. [PDF]

BMJ Open Qual
Atkins E, Birmpili P, Kellar I, Glidewell L, Cromwell DA.   +4 more
europepmc   +1 more source

Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun, Lingling Cui, Robert Terkeltaub, Ying Chen, Xinde Li, Xiaoyu Cheng, Tian Liu, Nicola Dalbeth, Changgui Li   +8 more
wiley   +1 more source

Special Issue on Ontologies and Data Management: Part I. [PDF]

Kunstliche Intell (Oldenbourg), 2020
Schneider T, Šimkus M.
europepmc   +1 more source

Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta‐Analysis

Arthritis Care &Research, EarlyView.
Objective Gastrointestinal perforation (GIP) is a rare and life‐threatening safety concern associated with JAK inhibitors (JAKi). We aimed to review the evidence regarding the risk of GIP associated with the use of JAKi in patients with rheumatoid arthritis (RA) using a systematic review and network meta‐analysis approach.
Thipsukhon Sathapanasiri, Manuel Meraz, Hamraz Mokri, Sajesh K Veettil, Karn Wijarnpreecha, Naomi Schlesinger, Arthur Kavanaugh, Nathorn Chaiyakunapruk   +7 more
wiley   +1 more source